CRVO Form 4: New Director Receives 8,100-Share Option Grant

Rhea-AI Filing Summary

CervoMed Inc. (CRVO) – Form 4 insider filing

On June 23, 2025 newly elected director Jeffrey V. Poulton received a non-qualified stock option for 8,100 common shares under the company’s 2025 Equity Incentive Plan. The option carries an exercise price of $6.52 and a ten-year term expiring June 23, 2035. Vesting occurs monthly in equal 1/12-increments beginning June 30, 2025 and completes after one year, contingent on continued board service.

No shares were bought or sold in the open market; the filing reflects an equity award customary for non-employee directors. Following the grant, Mr. Poulton beneficially owns 8,100 derivative securities and no change is reported for non-derivative holdings. The transaction was reported on June 25, 2025 and is categorized under Code “A” (grant) in Table II.

From an investor perspective, the filing is routine, modest in size and unlikely to materially impact the share count or near-term valuation, but it does strengthen director equity alignment.

Insights

Equity Compensation Analyst

TL;DR – Routine director option grant; immaterial dilution, modest alignment benefit.

This Form 4 discloses a standard non-employee director award: 8,100 options at $6.52 (approx. 0.1% of a 10 million-share float, if representative). Vesting over 12 months keeps incentives fresh while limiting immediate dilution because the award is out-of-the-money until the stock trades above $6.52. Such grants are common practice and signal no insider buying or selling sentiment. Given the small size, market impact should be negligible, yet the filing reminds investors that the board maintains equity exposure, which is generally viewed as governance-positive.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Poulton Jeffrey V.

(Last) (First) (Middle)

20 PARK PLAZA, SUITE 424

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.52	06/23/2025		A		8,100		(1)	06/23/2035	Common Stock	8,100	$0	8,100	D

Explanation of Responses:

1. On June 23, 2025, in connection with the Reporting Person's election to the Issuer's board of directors at its 2025 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,100 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2025, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ William R. Elder, attorney-in-fact for the Reporting Person	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CervoMed (CRVO) disclose in the latest Form 4?

The company granted director Jeffrey V. Poulton an option for 8,100 shares at $6.52 on June 23, 2025.

How many CRVO shares are covered by the new option grant?

8,100 shares of common stock.

What is the exercise price and expiration date of the option?

$6.52 per share; expires June 23, 2035.

When will the option granted to Jeffrey V. Poulton vest?

Monthly over one year in equal 1/12th increments starting June 30, 2025.

Does the Form 4 indicate any open-market buying or selling by insiders?

No, it only reports an equity award; no shares were bought or sold.